Download ico-008: human monoclonal antibody treating

iCo-008 is a type of antibody—called a monoclonal antibody—designed to target a protein
called eotaxin-1, which triggers inflammatory allergic reactions such as those found with
some ocular diseases, severe asthma and inflammatory bowel disease. Monoclonal
antibodies have the unique ability to bind to almost any substance, including disease
organisms in the human body. Through this targeting and binding process, iCo-008 blocks
eotaxin-1, neutralizing its ability to deliver the signal that triggers allergic reaction. iCo-008
is administered by intravenous injection.
ICO-008: HUMAN
MONOCLONAL ANTIBODY
TREATING BOTH THE BACK
AND FRONT OF THE EYE
EDEMA
POTENTIAL INDICATIONS
WET AGE-RELATED MACULAR
DEGENERATION (wAMD)
Ocular Markets
• Wet Age Related Macular Degeneration (wAMD)
• Vernal & Atopic Keratoconjunctivitis
• Conjunctiva
Systemic Markets
•
•
•
•
Inflammatory Bowel Disease, Crohn’s disease
Severe Asthma (License granted to Immune Pharmaceuticals)
Allergic rhinitis
Atopic dermatitis
PRODUCT HIGHLIGHTS
•
•
•
•
Human monoclonal antibody targeting eotaxin-1
Good safety & significant clinical history: Phase 1 & 2 (n=126)
iCo-008 utilizes a targeted, highly specific biological approach
Eotaxin binds with high affinity to CCR3
• Afflicts the elderly
• Leads to rapid vision loss
• N
ew literature implicates that
CCR3/Eotaxin-1 axis is a target for
AMD
LICENSING AGREEMENTS
In-licensing: Medimmune
• $400,000 up-front payment
• $7,000,000 milestone payments
• Exclusive rights to entire body
Out-licensing: Immune Pharma
• $500,000 upfront received
CLINICAL HISTORY
• $32,000,000 incoming milestones
Phase 1: (n=25) No serious adverse events
• 600,000 Immune shares
Phase 2: (n=101) Applied intranasally & topically to the eye
• 200,000 Immune warrants
• Safe and well tolerated
• Evidence of efficacy in severe allergy indication: reduced post allergy
nasal obstruction
• 6.14% ownership with dilution
provisions*
RECENT & UPCOMING MILESTONES
33 License systemic rights to Immune Pharmaceuticals for US$32+ million
while retaining ocular rights
❑❑ Pursuing non-dilutive funding for ocular programs
• Royalties on net sales
• R
etained WW rights to all ocular
applications
* As of the date of the transaction,
June 24, 2011
760-777 Hornby St.
Vancouver, BC, Canada V6Z 1S4
604-602-9414
www.icotherapeutics.com